Harraden Circle Investments’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Harraden Circle Investments’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,500,000	Closed	-$281K	–	193
2025 Q4	$281K	Hold	1,500,000	–	–	0.05%	103
2025 Q3	$326K	Hold	1,500,000	–	–	0.06%	82
2025 Q2	$180K	Hold	1,500,000	–	–	0.05%	81
2025 Q1	$195K	Buy	+1,500,000	New	+$211K	0.09%	65

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Harraden Circle Investments's DMAAR Position: Q1 2026 in Review

Harraden Circle Investments sold out of Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026, closing a stake of 1,500,000 shares — an estimated $281K sold.

Harraden Circle Investments first reported a position in DMAAR in Q1 2025 and held it in 4 quarters. The position peaked at $326K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

Harraden Circle Investments reported no remaining Drugs Made In America Acquisition Corp Rights position as of Q1 2026 after selling out during the quarter.
Harraden Circle Investments sold 1,500,000 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $281K.
Harraden Circle Investments first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and held it in 4 quarters.
Harraden Circle Investments's Drugs Made In America Acquisition Corp Rights position peaked at $326K in Q3 2025.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Harraden Circle Investments's 13F filing for Q1 2026, filed 15 May 2026.